SL-401
Phase 1Small molecule
SL-401 is one of 6 small molecule programs targeting Blastic Plasmacytoid Dendritic Cell Neoplasm. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
6 competitors in Blastic Plasmacytoid Dendritic Cell Neoplasm
#DrugCompanyPhaseTrials
1Venclexta
AbbViePhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Fludara
SanofiPhase 1
Vidaza
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 1
SL-401
DDana-Farber Cancer Institute
Phase 1
IMGN632
AbbViePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SL-401. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- DDana-Farber Cancer Institute